UDP-galactose glycosyltransferase (UGT (generic); specific forms have unique abbreviations, e.g., "β3GalT5" or "UGT8")

UDP-galactose-utilizing glycosyltransferases are a diverse group of enzymes that catalyze the transfer of galactose from UDP-galactose to a variety of acceptor molecules, such as proteins and lipids, as part of biosynthetic and metabolic processes. They play crucial roles in glycan and glycolipid biosynthesis, cellular signaling, and metabolic regulation. Members of this group include enzymes with critical functions in the central nervous system (e.g., UGT8 for myelin glycolipid production), drug metabolism, and cancer progression (e.g., β3GalT5). The term refers to a family with numerous isoforms, each with distinct tissue distributions, substrate specificities, and disease associations. Due to their involvement in cancer and metabolic regulation, selected members are considered therapeutic targets, although no drugs universally target this entire enzyme class at present.

Other names

UDP-galactosyltransferaseUDP-galactose glycosyltransferaseGalactosyltransferases (context-dependent; can refer to non-UDP-galactose enzymes as well)β3GalT5 (example, specific isoform)UGT8 (ceramide galactosyltransferase, specific isoform)

Drugs (hypothetically) modulate the enzymatic transfer of galactose moieties from UDP-galactose to acceptor molecules (inhibition or enhancement). Modulation of glycan biosynthesis pathways, potentially affecting cell signaling, recognition, or metabolism.